Navigation Links
AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
Date:8/3/2009

QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), its partner and licensee for perifosine in the North American market, has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for the Company's PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), in relapsed or relapsed/refractory multiple myeloma patients previously treated with bortezomib (VELCADE(R)). The SPA provides agreement that the Phase 3 study design adequately addresses objectives in support of a regulatory submission. The study, entitled, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib", will be a double-blind, placebo-controlled study comparing the efficacy and safety of perifosine vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, will enroll approximately 400 patients with relapsed or relapsed/refractory multiple myeloma. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety.

Juergen Engel, Ph. D., President and Chief Executive Officer of AEterna Zentaris commented, "We are very pleased and excited about perifosine moving forward into a Phase 3 trial. This represents a major milestone in our oncology drug development strategy which could hold great promise for patients with multiple myeloma."

About the Phase 3 Trial De
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
2. AEterna Zentaris Receives US$10 Million from Institutional Investors
3. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
4. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
5. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
6. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
7. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
8. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
9. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
10. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
11. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , that the global market RNA interference ... nearly $38.8 billion by 2018, with a five-year compound ... category, the fastest moving segment of the market, is ... of RNAi therapeutics has shown tremendous growth and has ...
(Date:8/1/2014)... Aug. 1, 2014 Glencoe Software, ... of "Data InPress" ( http://glencoesoftware.com/data-inpress.html ), a ... multidimensional image data into on-line publications.  The ... Video Injection Service. Photo - ... http://photos.prnewswire.com/prnh/20140731/132409 The DataViewer ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
Breaking Biology Technology:Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Midwest Biotech Leaders Featured On BioSpace Map 2
... Systems International (OTCBB: IFRS) subsidiary, AquaLiv, Inc., has ... Technology. AquaLiv received an overwhelming number ... of its recent announcement that its pilot HIV/AIDS ... on any active molecule. According to the announcement, ...
... 2011 PharmaNet Development Group, Inc. (the "Company" or "PharmaNet") ... and consent solicitation (the "Offer") for any and all of ... "Notes"), it has elected to extend the consent payment deadline ... on June 10, 2011, unless extended or earlier terminated (the ...
... of Mechanical Engineering at Stevens Institute of Technology, ... Roster as a candidate for grants to cooperate ... Department of State, the Fulbright Specialist Program places ... collaborations that strengthen the positions of US institutions. ...
Cached Biology Technology:Infrared Systems International's Subsidiary, AquaLiv Inc., Explains Its Revolutionary Technology in Layman's Terms 2Infrared Systems International's Subsidiary, AquaLiv Inc., Explains Its Revolutionary Technology in Layman's Terms 3PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation 2PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation 3PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation 4Dr. Frank Fisher of Stevens selected for Fulbright specialist roster 2
(Date:8/1/2014)... New Rochelle, NY, August 1, 2014Lesbian, gay, bisexual, and ... face the same problems as some of their heterosexual ... addition they often face additional physiological and legal ... most recent advances in assisted reproduction options is presented ... and Future Possibilities ," published in LGBT ...
(Date:8/1/2014)... INDIANAPOLIS, IN August 1, 2014 The Journal ... Best Article and Best Great Educational Material (GEM) awards, ... and Behavior (SNEB) annual conference, "Nutrition Education Impact: Local ... 1, 2014. These annual awards recognize the authors ... year in JNEB, as judged by members of the ...
(Date:8/1/2014)... new study, including two Simon Fraser University research ... and policymakers must collaborate closely on minimizing damage ... Viorel Popescu and Maureen Ryan, David H. Smith ... are among eight international co-authors of the newly ... the Environment . , Shale gas development is ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3
... PHOENIX, Ariz. Sept. 1, 2008 Researchers at ... new approach to treating endometrial cancer patients that not ... cancer cells. In a potentially major breakthrough, TGen ... in St. Louis discovered that introducing a particular inhibitor ...
... likely to die of - heart disease compared with women ... blame, according to a new University of Leicester led study ... New Blood Lecturer in Cardiovascular Medicine in the Department of ... "male disadvantage" may be related to the sex-specific effects of ...
... that increase the risk of developing inflammatory bowel disease ... to identify the specific disease-causing mutations in these new ... candidates to be added to the list of genes ... find genes that interact with each other and with ...
Cached Biology News:TGen and Washington University researchers discover new approach to treating endometrial cancer 2TGen and Washington University researchers discover new approach to treating endometrial cancer 3Sex hormones link to heart risk 2New genes found for inflammatory bowel disease in children 2New genes found for inflammatory bowel disease in children 3
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Validated and Silencer Pre-designed siRNAs, ...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Biology Products: